- Home
- KRC vs CPRX Comparison
KRC vs CPRX Comparison
Compare KRC & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KRC | CPRX |
|---|---|---|
| Founded | 1947 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.4B |
| IPO Year | 1996 | 2006 |
Fundamental Metrics
Financial Performance| Metric | KRC | CPRX |
|---|---|---|
| Price | $32.25 | $29.21 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 1 |
| Target Price | ★ $36.91 | $35.00 |
| AVG Volume (30 Days) | ★ 2.2M | 1.3M |
| Earning Date | 04-27-2026 | 05-06-2026 |
| Dividend Yield | ★ 6.78% | N/A |
| EPS Growth | ★ 31.07 | 28.24 |
| EPS | ★ 2.32 | 1.68 |
| Revenue | ★ $1,112,667,000.00 | $119,072,803.00 |
| Revenue This Year | N/A | $9.20 |
| Revenue Next Year | $2.13 | $10.51 |
| P/E Ratio | ★ $13.69 | $16.29 |
| Revenue Growth | N/A | ★ 16.39 |
| 52 Week Low | $27.36 | $19.05 |
| 52 Week High | $45.03 | $28.10 |
Technical Indicators
Market Signals| Indicator | KRC | CPRX |
|---|---|---|
| Relative Strength Index (RSI) | 67.27 | 73.50 |
| Support Level | $30.00 | $22.24 |
| Resistance Level | $43.30 | N/A |
| Average True Range (ATR) | 0.93 | 0.87 |
| MACD | 0.39 | 0.28 |
| Stochastic Oscillator | 94.63 | 93.75 |
Price Performance
Historical ComparisonAbout KRC Kilroy Realty Corporation
Kilroy Realty is a premier owner and landlord of approximately 16.3 million square feet of office space across Los Angeles, San Diego, the San Francisco Bay Area, Austin, Texas, and greater Seattle. The company operates as a real estate investment trust.
About CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.